NantBioScience, subsidiary of NantWorks, a company focused on the discovery and development of treatments for diseases with high unmet medical needs, announced a strategic collaboration with As part of the transaction,
According to the company, building on the nab (nanoparticle albumin-bound) technology platform, NantBioScience will create a pipeline of nab-based molecules. As part of the collaboration,
The objective of NantBioScience is to innovate drug development by testing molecularly targeted drugs, based on the molecular profile of the patient's tumor, independent of the cancer's anatomical type. With capabilities of next generation sequencing and targeted proteomics, each cancer may now be viewed as a series of rare diseases. These "omic" analytic tools and "big data" generated from supercomputing have been previously untapped on the scale now available in the field of drug development. NantBioScience and NantWorks are positioned to develop molecularly designed drugs in this era of genomics and proteomics, by identifying patients and their tumor signature at the most granular cellular, DNA and protein levels. Patients entering clinical trials would be identified after a "omic" analysis from tissue to cell to DNA to RNA to protein to peptide to drug, and tested based on this molecular profile to maximize clinical outcome and minimize side effects.
"We intend to make obsolete the standard method of clinical trial design of 'trial and error' and replace it with a level of quantitative predictability based on both the genomic and proteomic profile performed a priori. We also intend to make obsolete the common understanding that cancer treatments, developed under the age old dogma of 'maximum tolerated dose,' may work but only by wreaking terrible side effects, bringing patients to the brink of death," said NantWorks founder, Dr.
"We have invested over
In addition to the two nab product candidates, NantBioScience has a broad R&D program to discover new compounds that are specifically targeted at tumor signaling pathways in patients with specific genetic mutations. A novel inhibitor of oncogenic KRAS is showing promise in early development studies and will advance into a program of IND enabling studies in 2014. Normally a proto-oncogene, KRAS, when mutated to an oncogene, is transformed into the driver of tumorigenesis in pancreatic cancer amongst many other cancers and molecular profiles.
NantBioScience's pursuit of targeted therapies includes the discovery and development of drugs that remediate the activities of the often mutated tumor suppressor, p53. Because the loss of p53 functionality is a driver for the development of over 50 percent of all cancers and because p53 is responsible for maintaining the integrity of the cellular genome, pharmaceuticals targeting cells harboring p53 mutations are coveted. NantBioScience plans to initiate IND-enabling studies on its lead p53 remediating compound, for which NantBioScience is targeting a first-in-man study in 2015.
NantBioScience's pipeline also contains novel potent multi- kinase inhibitors. These compounds are entering into a program of IND-enabling studies, with first-in-man studies planned for 2016. NantBioScience's kinase inhibitor program is further buoyed by its library of >4,000 multi-kinase inhibitors which are currently under investigation for a variety of indications and molecular profiles.
As part of the collaboration,
The transaction is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and is expected to close in the first quarter of 2014.
NantBioScience, a subsidiary of NantWorks, is a biopharmaceutical company.
((Comments on this story may be sent to email@example.com))
NantBioScience, subsidiary of NantWorks, a company focused on the discovery and development of treatments for diseases with high unmet medical needs, announced a strategic collaboration with
As part of the transaction,